Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will 'Businessman' Trump See The Value In Indian Generics?

Executive Summary

The election of Donald Trump as the next US president might suggest a degree of policy unpredictability for pharma companies but Indian firms are hoping that the businessman in the real estate mogul and President-elect will see the value that generics offer.

You may also be interested in...



Banknote Ban Boosts Business At India E-Pharmacy Start-Ups

Other retailers may be feeling the pain, but India’s nascent e-pharmacy sector says business is better than ever since the country’s prime minister outlawed 86% of the cash in circulation to address tax avoidance.

Trump Victory To Breathe Life Into Korean Biopharmas?

South Korean analysts and pharma firms are generally viewing Donald Trump's win in the US presidential election as positive for the sector, which is stepping up efforts to enter global markets including the US.

China Keeping Eye On Key Regulatory Dialog After Trump Win

Although Chinese President Xi Jinping has expressed the country's willingness to work with the newly elected US president to promote ties in a constructive way, potential setbacks for bilateral trade and regulatory talks are worrying observers.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel